Physician profile
Robert W Weller
NPI 1669445458
$1,992.51
in general payments reported to CMS, 2019-2025
14 companies · $530 in 2025
The $530 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $229 · 2021: $90.48 · 2022: $69.96 · 2023: $352 · 2024: $245 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,127.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $308.70 | 2020-2025 | Clareon, Argos, Rocklatan |
| Regeneron Healthcare Solutions, INC. | $277.13 | 2019-2025 | Eylea Hd |
| Astellas Pharma US INC | $247.64 | 2023-2025 | Izervay |
| Genentech USA, INC. | $217.00 | 2023-2025 | Vabysmo |
| Abbvie INC. | $195.28 | 2022-2025 | Alphagan P, Lumigan |
| Johnson & Johnson Surgical Vision, INC. | $191.49 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $143.58 | 2019-2022 | |
| Ivantis, INC | $110.00 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $99.34 | 2025 | Xdemvy |
| Allergan, INC. | $95.21 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $47.12 | 2019 | |
| Sun Pharmaceutical Industries INC. | $29.47 | 2024-2025 | |
| Glaukos Corporation | $16.08 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $14.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Weller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.